作者:Carroll Temple、Glynn P. Wheeler、Robert D. Elliott、Jerry D. Rose、Robert N. Comber、John A. Montgomery
DOI:10.1021/jm00355a018
日期:1983.1
Certain derivatives containing the 1,2-dihydropyrido[3,4-b]pyrazine (1-deaza-7,8-dihydropteridine) ring system are active against experimental neoplasms in mice. The mechanism of action of these agents has been attributed to the accumulation of cells at mitosis. Identification of the structural features that are necessary for activity was accomplished by evaluation of modified 1-deazapteridines and
某些含有1,2-二氢吡啶并[3,4-b]吡嗪(1-deaza-7,8-dihydropteridine)环系统的衍生物具有抗小鼠实验肿瘤的活性。这些试剂的作用机理已归因于有丝分裂时细胞的积累。活性必需的结构特征的鉴定是通过评估修饰的1-脱氮哌啶以及开环和开环的类似物来完成的。相对于4-氨基-1-脱氮基-7,8-二氢-6-[((N-甲基苯胺基)甲基]蝶啶-2-氨基甲酸酯(11)和相应的6-苯基化合物(12),没有抗肿瘤活性用7,8-二氢蝶啶,3-deaza-7,8-二氢蝶啶和相应的杂芳族化合物观察到。而且,当1-deaza-7,8-dihydropteridines氧化为1-deazapteridines或还原为1-deaza-5时,活性会降低或破坏。6,7,8-四氢蝶啶。另外,用其他取代基取代4-氨基会破坏活性。似乎需要具有芳基的6位取代基,这对于活性是必要的,当在7位上取代甲基时,活性会增加。